20,000 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Bought by Caption Management LLC

Caption Management LLC purchased a new stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,000 shares of the company’s stock, valued at approximately $274,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in MYGN. Captrust Financial Advisors boosted its stake in Myriad Genetics by 36.6% during the 4th quarter. Captrust Financial Advisors now owns 20,593 shares of the company’s stock valued at $282,000 after purchasing an additional 5,519 shares during the period. Balyasny Asset Management L.P. bought a new stake in shares of Myriad Genetics in the fourth quarter valued at approximately $1,143,000. BNP Paribas Financial Markets grew its stake in shares of Myriad Genetics by 51.1% in the fourth quarter. BNP Paribas Financial Markets now owns 69,183 shares of the company’s stock worth $948,000 after acquiring an additional 23,408 shares during the last quarter. Algert Global LLC increased its position in Myriad Genetics by 182.4% during the fourth quarter. Algert Global LLC now owns 60,098 shares of the company’s stock worth $824,000 after acquiring an additional 38,818 shares during the period. Finally, Schonfeld Strategic Advisors LLC raised its stake in Myriad Genetics by 78.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 32,920 shares of the company’s stock valued at $451,000 after purchasing an additional 14,475 shares during the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on MYGN. Guggenheim downgraded shares of Myriad Genetics from a “buy” rating to a “neutral” rating in a report on Wednesday, April 9th. The Goldman Sachs Group cut their price target on Myriad Genetics from $14.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday. Craig Hallum set a $18.00 price objective on Myriad Genetics and gave the stock a “buy” rating in a report on Wednesday. Stephens reaffirmed an “equal weight” rating and issued a $20.00 target price on shares of Myriad Genetics in a research report on Thursday, January 16th. Finally, Wells Fargo & Company lowered shares of Myriad Genetics from an “overweight” rating to an “equal weight” rating and set a $6.00 price target on the stock. in a report on Wednesday. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Myriad Genetics has a consensus rating of “Hold” and a consensus target price of $16.04.

Myriad Genetics Stock Performance

NASDAQ:MYGN opened at $4.26 on Thursday. The stock has a market capitalization of $392.74 million, a P/E ratio of -3.28 and a beta of 2.01. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. Myriad Genetics, Inc. has a 1 year low of $4.24 and a 1 year high of $29.30. The firm has a 50 day moving average of $8.61 and a 200-day moving average of $12.82.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.02. Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The firm had revenue of $195.90 million during the quarter, compared to the consensus estimate of $200.37 million. During the same quarter in the previous year, the company posted ($0.01) EPS. The business’s revenue for the quarter was down 33.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Myriad Genetics, Inc. will post -0.3 EPS for the current fiscal year.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.